|
mRNA Vaccines: A Solution for Future Health Challenges
|
Mohammad Hassan Darvishi   , Hamidreza Javadi * |
| Nanobiotechnology Research Center, Institute of New Health Technologies, Baqiyatallah University of Medical Sciences, Tehran, Iran , hjavadi53r@gmail.com |
|
|
Abstract: (4 Views) |
Global concerns regarding infectious diseases have not ended with the control of COVID-19. Existing and emerging threats continue to exert a significant impact on the global population and, consequently, on the population of Iran. The increasing incidence of re-emerging and emerging infectious diseases, rising antimicrobial resistance, and declining vaccination coverage in developing countries have intensified the World Health Organization’s concerns about global health. Emerging infectious diseases often encounter little to no effective immunity in human populations, rendering them highly contagious and potentially dangerous. Their unpredictable nature and rapid spread pose substantial challenges to healthcare systems in terms of preparedness, response, and effective control.
Many emerging infectious diseases, as observed during the COVID-19 pandemic, are the result of increased human-animal interactions, with their spread further amplified by the expansion of international travel and population mobility. Large-scale vaccine production, rapid and timely vaccination, and the deployment of effective vaccines play a critical role in controlling such infections and preventing pandemics and their rapid and dangerous dissemination. Although different vaccine platforms have distinct advantages and limitations, the COVID-19 pandemic clearly demonstrated that investment in research, development, and infrastructure for next-generation vaccines -particularly mRNA-based vaccines- is an essential requirement for national health systems.
Given the rapid transmission and high mutation rates of these pathogens, leading to the continuous emergence of new variants, it is imperative to select appropriate vaccine platforms and to develop the necessary infrastructure for research and development, large-scale production of effective vaccines, and the establishment of a vaccine candidate bank. Such capacities can play a crucial role not only in addressing challenges posed by emerging and re-emerging infectious diseases, but also in the prevention and treatment of certain cancers. Accordingly, this article highlights the rationale for selecting and developing infrastructure for selected next-generation vaccine platforms. |
|
| Keywords: Next-generation vaccines, Emerging and re-emerging infectious diseases, Vaccine platforms, COVID-19 |
|
|
Full-Text [PDF 340 kb]
(7 Downloads)
|
Type of Study: Policy Brief |
Subject:
Marine Medicine
Received: 2026/01/7 | Accepted: 2026/01/25 | Published: 2026/01/30
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
